EyePoint Pharmaceuticals (NASDAQ:EYPT) Coverage Initiated by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. began coverage on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) in a research note published on Monday morning, Marketbeat.com reports. The firm issued an overweight rating and a $35.00 target price on the stock. A number of other research analysts have also recently issued reports on the company. Capital One […]

Related Keywords

China ,Darioa Paggiarino ,Dekabank Deutsche Girozentrale ,Woodstock Corp ,Mirae Asset Global Investments Co ,Securities Exchange Commission ,Nasdaq ,Eyepoint Pharmaceuticals Inc ,Analyst Recommendations For Eyepoint Pharmaceuticals ,Jpmorgan Chase Co ,Institutional Trading Of Eyepoint Pharmaceuticals ,China Universal Asset Management Co ,Eyepoint Pharmaceuticals ,Investment Advisers ,News Ratings For Eyepoint Pharmaceuticals Daily ,Eyepoint Pharmaceuticals Stock Performance ,Free Report ,One Financial ,Moderate Buy ,Point Pharmaceuticals ,Get Free Report ,Michael Craig Pine ,Exchange Commission ,Asset Global Investments ,Bank Deutsche Girozentrale ,Universal Asset Management ,Eyepoint Pharmaceuticals Daily ,Nasdaq Eypt ,Eypt ,Medical ,Initiated Coverage ,